WallabyPhenox PROMISE Registry of MeVO Stroke Treatment Begins Enrollment

August 14, 2026—WallabyPhenox announced that the first patient has been enrolled in the PROMISE registry, an investigator-initiated, prospective study on the management of ischemic stroke secondary to medium vessel occlusion (MeVO) acute ischemic stroke.

According to WallabyPhenox, the company-sponsored study is examining how MeVO-related strokes are managed within the first 24 hours. The registry is planned to enroll patients across 30 sites in the United States.

The press release noted that the study is designed to capture real-world practice across participating sites and help characterize the current equipoise among treating physicians, enrolling patients managed with mechanical thrombectomy and patients treated medically. Patients will be followed for 6 months.

The PROMISE Global Principal Investigator is Kaustubh Limaye, MD, Associate Professor at Indiana University Medical Center in Indianapolis, Indiana.

“Management for MeVO-related stroke is one of the next frontiers in advancing care for stroke patients,” commented Dr. Limaye in WallabyPhenox’s press release. “We planned this study to better understand the practice and challenges involved in management of these patients in a prospective, unbiased way. To achieve a higher level of nuanced understanding we planned the imaging to be core-lab adjudicated. I thank WallabyPhenox for their support to this investigator-initiated project.”

The first patient in the study was enrolled at IU Health Methodist Hospital in Indianapolis, where Devi Patra, MD, and Ann Jones, MD, are colead investigators.

Dr. Patra, a neuroendovascular surgeon at Indiana University Medical Center, stated in the company’s press release, “This important study is expected to help answer a critical clinical question: whether revascularization attempt benefits patients with MeVO. Current evidence remains largely equivocal, underscoring the need for clearer data to guide treatment decisions.”

Michael Froehler, MD, Director of the Cerebrovascular Program at Vanderbilt University Medical Center in Nashville, Tennessee, added, “This study is important because it includes all MeVO patients; not just those treated endovascularly. The results will help us to understand real-world MeVO outcomes.”

WallabyPhenox is global neurovascular company with headquarters in Irvine, California, and Shanghai, China, that is developing devices for the treatment of ischemic and hemorrhagic stroke. In April 2022, Wallaby Medical announced that it had acquired Germany-based Phenox GmbH, including Phenox’s Femtos GmbH. The companies had been strategic partners since 2019.